Discovery Laboratories, Inc. is a biotechnology company developing surfactant therapies to treat respiratory disorders and diseases. The Company?s KL4 technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung

and essential for survival and normal respiratory function. In addition, its capillary aerosol-generating technology (capillary aerosolization technology) produces a dense aerosol with a defined particle size, to deliver its aerosolized KL4 surfactant to the lung. The Company is developing its products, Surfaxin(lucinactant), Surfaxin LS and Aerosurf, to address the respiratory conditions affecting neonatal populations. It has filed a New Drug Application (NDA) for its product based on its KL4 surfactant technology, Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.